# A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

> **NCT05626803** · PHASE2 · COMPLETED · sponsor: **Vaxart** · enrollment: 135 (actual)

## Conditions studied

- Norovirus Infections

## Interventions

- **DRUG:** Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
- **DRUG:** Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
- **DRUG:** Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05626803
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-26
- **Primary completion:** 2023-10-16
- **Final completion:** 2023-10-16
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626803, "A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05626803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*